遗传风险评分与结直肠癌筛查人群中进展期肿瘤患病率相关
在德国一项筛查结肠镜研究中,基于48个结直肠癌相关单核苷酸多态性(SNP)计算遗传风险评分(GRS),纳入1043名50-79岁参与者。GRS升高与进展期肿瘤患病率升高相关,但与非进展期腺瘤无关,最高三分位者风险约为最低三分位的2.7倍,作者认为该发现或可用于定义风险适配的筛查年龄。
要点
- GRS中三分位和高三分位者进展期肿瘤风险分别约为低三分位者的2.2倍和2.7倍。
- GRS与进展期肿瘤的关联在近端进展期肿瘤中OR最大,中三分位OR 3.55,高三分位OR 3.61。
- GRS与非进展期腺瘤无显著关联,中三分位OR 1.09,高三分位OR 1.05,95%CI均跨1。
核心结论
- 在德国结直肠癌筛查研究参与者的遗传分析中,基于结直肠癌相关SNP的GRS升高与进展期肿瘤患病率升高相关。
- 作者认为这些发现或可用于定义风险适配的筛查年龄。
研究设计与样本
- 基于48个结直肠癌相关SNP(经全面文献检索确定)计算GRS。
- 从德国一项筛查结肠镜研究中获取1043名50-79岁参与者的遗传数据,招募时间为2005年至2013年。
- 参与者包括294例进展期肿瘤、249例非进展期腺瘤(NAA)和500例无肿瘤者。
- 采用多重逻辑回归计算进展期肿瘤和NAA的风险,并计算风险进展期。
- 使用田纳西结直肠息肉研究的一个子集数据重复验证 findings。
主要发现
- GRS升高与进展期肿瘤患病率升高相关,但与NAA无关。
- GRS中三分位和高三分位者进展期肿瘤风险分别较低三分位者增加2.2倍和2.7倍。
- NAA的中三分位调整OR为1.09(95%CI 0.76-1.57),高三分位调整OR为1.05(95%CI 0.70-1.55)。
- 近端进展期肿瘤的OR最大:中三分位OR 3.55(95%CI 1.85-6.82),高三分位OR 3.61(95%CI 1.84-7.10)。
- 中GRS vs 低GRS的风险进展期为13.4年(95%CI 4.8-22.0),高GRS vs 低GRS为17.5年(95%CI 7.8-27.3)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: The presence of specific single nucleotide polymorphisms (SNPs) can be used to calculate an individual's risk for colorectal cancer (CRC), called a genetic risk score (GRS). We investigated whether GRS can identify individuals with clinically relevant neoplasms in a screening colonoscopy population. METHODS: We derived a GRS based on 48 SNPs associated with CRC, identified in a comprehensive literature search. We obtained genetic data from 1043 participants (50-79 years old) in a screening colonoscopy study in Germany, recruited from 2005 through 2013 (294 with advanced neoplasms, 249 with non-advanced adenoma (NAAs), and 500 without neoplasms). Each participant was assigned a GRS by aggregating their risk alleles (0, 1, or 2). Risk of advanced neoplasms and NAA according to GRS was calculated by multiple logistic regression. Risk advancement periods were calculated. We replicated our findings using data from a subset of the Tennessee Colorectal Polyp Study. RESULTS: An increased GRS was associated with higher prevalence of advanced neoplasms, but not NAAs. Participants in the middle and upper tertiles of GRS had a 2.2-fold and 2.7-fold increase in risk, respectively, of advanced neoplasms compared to those in the lower tertile. Adjusted odds ratios (ORs) were 1.09 (95% confidence interval [CI], 0.76-1.57) for NAA in the middle tertile and 1.05 (95% CI, 0.70-1.55) for NAA in the upper tertile. The ORs were largest for proximal advanced neoplasms for participants in the middle tertile (OR, 3.55; 95% CI 1.85-6.82) and the upper tertile (OR, 3.61; 95% CI 1.84-7.10). The risk advancement period for medium vs low GRS was 13.4 years (95% CI 4.8-22.0) and for high vs low GRS was 17.5 years (95% CI, 7.8-27.3). CONCLUSIONS: In a genetic analysis of participants in a CRC screening study in Germany, an increased GRS (based on CRC-associated SNPs) was associated with increased prevalence of advanced neoplasms. These findings might be used in defining risk-adapted screening ages.
引用
- Weigl K, Thomsen H, Balavarca Y, et al. Genetic Risk Score Is Associated With Prevalence of Advanced Neoplasms in a Colorectal Cancer Screening Population. Gastroenterology. 2018. PMID: 29574091. doi:10.1053/j.gastro.2018.03.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。